Overview

Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Subjects With Cognitive Impairment Associated With Schizophrenia

Status:
Recruiting

Trial end date:
2025-03-01

Target enrollment:

Participant gender:

Summary

Study to evaluate the safety and efficacy of luvadaxistat compared with placebo on improving cognitive performance in subjects with schizophrenia.

Phase:

Phase 2

Details

Lead Sponsor:

Neurocrine Biosciences